10:18 AM EDT, 07/15/2024 (MT Newswires) -- Lantheus Holdings ( LNTH ) said Friday it has acquired Meilleur Technologies, including NAV-4694, expanding its Alzheimer's disease pipeline.

NAV-4694, a B amyloid positron emission tomography imaging agent in Phase 3 development, is used in academic and industry investigational therapeutic trials.

Under the terms of the deal, Lantheus ( LNTH ) will make upfront, milestone, and royalty payments, while Meilleur will provide transition and clinical development services post-closing, according to the company statement.

Financial details of the deal were not disclosed.

Price: 123.26, Change: -0.17, Percent Change: -0.13